Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • Corporate Governance Reports
      • Annual General Meeting (AGM)
      • Articles of Association
      • Board of Directors
      • Committees
      • Auditor
      • Group management
      • Incentive programs
    • Current general meeting
    • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2022
      • World Mitochondrial Disease Week 2021
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Press releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
23 May, 2023
Regulatory

Abliva AB Interim Report January – March 2023

Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Continue reading
24 February, 2023
Regulatory

Abliva AB Year-End Report January – December 2022

A successful financing enabled the start of the FALCON study with KL1333
Continue reading
22 November, 2022
Regulatory

Abliva AB Interim Report January – September 2022

Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Continue reading
19 August, 2022
Regulatory

Abliva AB Interim Report January – June 2022

SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Continue reading
31 May, 2022
Regulatory

Abliva AB Interim Report January – March 2022

First quarter summary
Continue reading
22 February, 2022
Regulatory

Abliva AB Year-End Report January – December 2021

"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO
Continue reading
19 November, 2021
Regulatory

Abliva AB Interim Report January – September 2021

Endpoint validated enables KL1333 Phase 2/3 study start ⎮ Favorable feedback supports progressing NV354 into Phase 1
Continue reading
19 August, 2021
Regulatory

Abliva AB Interim Report January – June 2021

Second quarter summary
Continue reading
20 May, 2021
Regulatory

Abliva AB Interim Report January – March 2021

First quarter summary
Continue reading
19 February, 2021
Regulatory

Abliva AB Year-End Report January – December 2020

2020 summary
Continue reading
20 November, 2020
Regulatory

Abliva AB Interim Report January – September 2020

KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Continue reading
21 August, 2020
Regulatory

Abliva AB Interim Report January – June 2020

NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Continue reading

Posts navigation

Older posts

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • Current general meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all